Telix Pharmaceuticals: FDA accepts Pixclara NDA

The Telix Pharmaceuticals Ltd (ASX: TLX) share price is in the spotlight after the FDA accepted its New Drug Application for TLX101-Px (Pixclara®), a PET imaging agent for glioma. TLX101-Px has received Orphan Drug and Fast Track status, with a key regulatory decision expected by September.

What did Telix Pharmaceuticals report?

• The US FDA accepted Telix’s NDA for TLX101-Px (Pixclara®), a PET agent for imaging brain cancer (glioma)
• The Prescription Drug User Fee Act (PDUFA) goal date is 11 September 2026
• TLX101-Px holds Orphan Drug and Fast Track designations in the US
• No FY 2026 revenue guidance has been assigned to TLX101-Px pending approval
• TLX101-Px aimed at addressing an unmet medical need in both adult and paediatric glioma cases

What else do investors need to know?

The FDA’s acceptance of the Telix NDA marks a key step toward potential commercialisation of TLX101-Px in the United States. This diagnostic agent aims to improve the differentiation between recurrent glioma and treatment-related changes, a persistent challenge in neuro-oncology.

TLX101-Px is expected to complement Telix’s broader LAT1-targeting therapeutic pipeline, notably the TLX101-Tx therapy under investigation in the IPAX-BrIGHT clinical trial. There are currently no marketing authorisations for TLX101-Px or TLX101-Tx in any region.

Telix has reaffirmed that FY 2026 guidance does not anticipate revenue for TLX101-Px, pending the FDA decision. The product could provide both clinical impact and financial upside if approved in the future.

What’s next for Telix Pharmaceuticals?

Investors can expect further updates as Telix works with the FDA ahead of the September 2026 goal date for TLX101-Px. The company is also advancing late-stage trials for related therapies, aiming to build a broader radiopharmaceutical portfolio for oncology and rare diseases.

Looking ahead, a successful approval could see Telix expand its presence in the US diagnostics market while pursuing commercial opportunities for both imaging and therapeutic candidates.

Telix Pharmaceuticals share price snapshot

Over the past year, Telix Pharmaceuticals shares have declined 49%, trailing the S&P/ASX 200 Index (ASX: XJO) which has risen 16% over the same period.

View Original Announcement

The post Telix Pharmaceuticals: FDA accepts Pixclara NDA appeared first on The Motley Fool Australia.

More reading

• Where is the value amongst ASX healthcare shares?
• Monadelphous wins $145m of new and renewed resources sector contracts
• Fortescue accelerates world’s first large-scale industrial green energy grid
• 7 ASX 200 shares just upgraded to strong buy ratings
• 5 things to watch on the ASX 200 on Friday

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.